SCHEMBL29504337

SCHEMBL29504337

CC(C)(C)OC(=O)N1CCC[C@H](Nc2cc(Br)c(F)cc2[N+](=O)[O-])C1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.43
GPR174 Q9BXC1 4/20 0.40
FPR3 P25089 1/20 0.40
FPR2 P25090 1/20 0.40
HDAC4 P56524 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
SCN9A Q15858 1/20 0.39
BTK Q06187 2/20 0.39
TRPV3 Q8NET8 1/20 0.38
KCNH2 Q12809 1/20 0.38
MAPT P10636 3/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31192611 1.00 USP30 (0.43) USP30GPR174FPR3FPR2HDAC4
SCHEMBL28706695 1.00 USP30 (0.43) USP30GPR174FPR3FPR2HDAC4
SCHEMBL29504296 1.00 USP30 (0.43) USP30GPR174FPR3FPR2HDAC4
SCHEMBL28706693 1.00 USP30 (0.43) USP30GPR174FPR3FPR2HDAC4
SCHEMBL31192615 0.94 USP30 (0.42) USP30GPR174FPR3FPR2KCNH2
SCHEMBL29504228 0.94 USP30 (0.42) USP30GPR174FPR3FPR2KCNH2
SCHEMBL29504358 0.94 USP30 (0.42) USP30GPR174FPR3FPR2KCNH2
SCHEMBL31192569 0.94 USP30 (0.42) USP30GPR174FPR3FPR2KCNH2
SCHEMBL28695865 0.90 USP30 (0.42) USP30GPR174KCNH2MAPTALDH1A1
SCHEMBL4648329 0.89 ALDH1A1 (0.46) GPR174KCNH2MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3976604-B1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2026-01-21 EP disclosed
US-20230092890-A1 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) 2023-03-23 US disclosed
EP-3976604-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2022-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230092890-A1 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same HDAC6, HDAC1, HDAC2 USP30 1125/4885GPR174 4432/4885FPR3 3461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.